A Multicenter, Open-label, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous And/or Intravenous Pf-06741086 In Subjects With Severe Hemophilia

Trial Profile

A Multicenter, Open-label, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous And/or Intravenous Pf-06741086 In Subjects With Severe Hemophilia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs PF 6741086 (Primary) ; PF 6741086 (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2017 Planned End Date changed from 25 Nov 2018 to 30 Nov 2018.
    • 18 May 2017 Planned primary completion date changed from 25 Nov 2018 to 30 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top